JP2001509488A - 敗血症治療薬、その製造及び使用 - Google Patents
敗血症治療薬、その製造及び使用Info
- Publication number
- JP2001509488A JP2001509488A JP2000501768A JP2000501768A JP2001509488A JP 2001509488 A JP2001509488 A JP 2001509488A JP 2000501768 A JP2000501768 A JP 2000501768A JP 2000501768 A JP2000501768 A JP 2000501768A JP 2001509488 A JP2001509488 A JP 2001509488A
- Authority
- JP
- Japan
- Prior art keywords
- lbp
- lps
- sepsis
- protein
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 239000004599 antimicrobial Substances 0.000 title 1
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 claims abstract description 37
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 claims abstract description 35
- 206010040047 Sepsis Diseases 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 3
- 239000002158 endotoxin Substances 0.000 claims description 19
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 19
- 241000701447 unidentified baculovirus Species 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000192125 Firmicutes Species 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 101150072740 Lbp gene Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 102100033735 Bactericidal permeability-increasing protein Human genes 0.000 claims 2
- 101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 claims 1
- 241001529572 Chaceon affinis Species 0.000 claims 1
- 101000779583 Limulus polyphemus Anti-lipopolysaccharide factor Proteins 0.000 claims 1
- 101001023407 Mus musculus Lipopolysaccharide-binding protein Proteins 0.000 claims 1
- 101001023403 Rattus norvegicus Lipopolysaccharide-binding protein Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 102100035131 Lipopolysaccharide-binding protein Human genes 0.000 abstract description 4
- 241001529936 Murinae Species 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000688 bacterial toxin Substances 0.000 description 5
- 231100000699 Bacterial toxin Toxicity 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 101710089435 Lipopolysaccharide-binding protein Proteins 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000009716 hepatic expression Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19729810.9 | 1997-07-11 | ||
| DE19729810A DE19729810C2 (de) | 1997-07-11 | 1997-07-11 | Mittel zur Sepsistherapie, seine Herstellung und seine Verwendung |
| PCT/DE1998/000964 WO1999002178A1 (de) | 1997-07-11 | 1998-04-04 | Mittel zur sepsistherapie, seine herstellung und seine verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001509488A true JP2001509488A (ja) | 2001-07-24 |
| JP2001509488A5 JP2001509488A5 (https=) | 2005-12-22 |
Family
ID=7835437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000501768A Pending JP2001509488A (ja) | 1997-07-11 | 1998-04-04 | 敗血症治療薬、その製造及び使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6949512B1 (https=) |
| EP (1) | EP0999849B1 (https=) |
| JP (1) | JP2001509488A (https=) |
| AT (1) | ATE223227T1 (https=) |
| DE (2) | DE19729810C2 (https=) |
| DK (1) | DK0999849T3 (https=) |
| ES (1) | ES2183376T3 (https=) |
| PT (1) | PT999849E (https=) |
| WO (1) | WO1999002178A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011520422A (ja) * | 2008-04-09 | 2011-07-21 | フォルシュンクスツェントルム ボルステール − ライプニッツエントルム フュール メディツィン ウント ビオヴィッセンシャフテン | 新規抗菌ペプチド |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0760849A1 (en) * | 1993-04-30 | 1997-03-12 | Incyte Pharmaceuticals, Inc. | Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof |
| WO1995005393A2 (en) * | 1993-08-18 | 1995-02-23 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Lipopolysaccharide-binding and neutralizing peptides |
| WO1995008560A1 (en) * | 1993-09-24 | 1995-03-30 | Centocor, Inc. | Novel peptides useful for inhibiting binding of lipopolysaccharides (lps) by lipopolysaccharide binding protein (lbp) |
| US5837810A (en) * | 1994-03-15 | 1998-11-17 | The Scripps Research Institute | Polypeptides of lipopolysaccharide binding protein |
| US5990082A (en) * | 1997-10-22 | 1999-11-23 | Xoma Corporation | Uses of lipopolysaccharide binding protein |
-
1997
- 1997-07-11 DE DE19729810A patent/DE19729810C2/de not_active Expired - Fee Related
-
1998
- 1998-04-04 PT PT98928139T patent/PT999849E/pt unknown
- 1998-04-04 EP EP98928139A patent/EP0999849B1/de not_active Expired - Lifetime
- 1998-04-04 DK DK98928139T patent/DK0999849T3/da active
- 1998-04-04 AT AT98928139T patent/ATE223227T1/de not_active IP Right Cessation
- 1998-04-04 ES ES98928139T patent/ES2183376T3/es not_active Expired - Lifetime
- 1998-04-04 WO PCT/DE1998/000964 patent/WO1999002178A1/de not_active Ceased
- 1998-04-04 JP JP2000501768A patent/JP2001509488A/ja active Pending
- 1998-04-04 DE DE59805440T patent/DE59805440D1/de not_active Expired - Lifetime
-
2000
- 2000-01-13 US US09/484,121 patent/US6949512B1/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011520422A (ja) * | 2008-04-09 | 2011-07-21 | フォルシュンクスツェントルム ボルステール − ライプニッツエントルム フュール メディツィン ウント ビオヴィッセンシャフテン | 新規抗菌ペプチド |
Also Published As
| Publication number | Publication date |
|---|---|
| DK0999849T3 (da) | 2003-01-06 |
| PT999849E (pt) | 2003-01-31 |
| ATE223227T1 (de) | 2002-09-15 |
| WO1999002178A1 (de) | 1999-01-21 |
| US6949512B1 (en) | 2005-09-27 |
| DE19729810A1 (de) | 1999-01-14 |
| DE19729810C2 (de) | 2000-01-13 |
| DE59805440D1 (de) | 2002-10-10 |
| EP0999849A1 (de) | 2000-05-17 |
| ES2183376T3 (es) | 2003-03-16 |
| EP0999849B1 (de) | 2002-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Engerman et al. | Experimental diabetic retinopathy in dogs | |
| JPH08511682A (ja) | 組み換えｂｐｉ蛋白およびｌｂｐ蛋白、それをコードする核酸分子、その生産方法並びにそれらの使用 | |
| Gehanno et al. | A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus | |
| US4916117A (en) | Treatment of inflammation using alpha 1-antichymotrypsin | |
| JP2000509715A (ja) | 炎症を処置するための方法 | |
| JP2704880B2 (ja) | アンギオゲニンの抑制剤 | |
| JP4463885B2 (ja) | 劇症肝炎疾患治療剤 | |
| JP2001509488A (ja) | 敗血症治療薬、その製造及び使用 | |
| JP2784401B2 (ja) | 慢性骨髄性白血病の治療方法 | |
| Creasey et al. | Pharmacokinetics of aztreonam in elderly male volunteers. | |
| CN118766933A (zh) | Aldisin化合物在制备治疗炎症性肠病的药物中的应用 | |
| EP0504191B1 (en) | Method and composition for the treatment of mammalian hiv infection | |
| Medici et al. | Effects of drugs on mucus glycoproteins and water in bronchial secretion | |
| JP2000517322A (ja) | インターロイキン―９とそのアンタゴニストを使用することによって異常を治療する方法 | |
| US7306791B2 (en) | Agent for preventing and/or treating multiple organ failure | |
| CN112190708B (zh) | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 | |
| CN109846863B (zh) | 和厚朴酚的用途 | |
| CN114748609A (zh) | 基于clec18a蛋白的预防和抑制机体炎症反应药物及应用 | |
| WO1983004260A1 (fr) | Enzyme analogue de la pepsine de leucocyte humain et agent therapeutique contenant cette enzyme en tant qu'ingredient effectif pour le traitement de troubles allergiques, de maladies auto-immunitaires et de tumeurs | |
| US20060067913A1 (en) | HCV therapy | |
| US5750501A (en) | Method and composition for treatment of patients having decompensated liver disease | |
| KR20050034584A (ko) | Ｓｉｒｓ/패혈증의 치료 및 예방 방법 및 이를 위한조성물 | |
| JP4114979B2 (ja) | 拡張型心筋症治療剤 | |
| CN120531854A (zh) | 多肽Nod-T3在制备治疗肺部疾病药物中的应用 | |
| JPH10273446A (ja) | 腎疾患予防及び／又は治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050325 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080527 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080821 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080828 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090210 |